| pubmed-article:11839442 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11839442 | lifeskim:mentions | umls-concept:C0021826 | lld:lifeskim |
| pubmed-article:11839442 | lifeskim:mentions | umls-concept:C0037628 | lld:lifeskim |
| pubmed-article:11839442 | lifeskim:mentions | umls-concept:C0220777 | lld:lifeskim |
| pubmed-article:11839442 | lifeskim:mentions | umls-concept:C0205251 | lld:lifeskim |
| pubmed-article:11839442 | lifeskim:mentions | umls-concept:C0391448 | lld:lifeskim |
| pubmed-article:11839442 | pubmed:issue | 1-2 | lld:pubmed |
| pubmed-article:11839442 | pubmed:dateCreated | 2002-2-12 | lld:pubmed |
| pubmed-article:11839442 | pubmed:abstractText | The aim of this study was to determine the intestinal absorption characteristics of the antiviral agent UC-781 and to optimize the experimental conditions of the in vitro system for low solubility compounds. The absorption potential of UC-781 was studied with the Caco-2 system and with the rat intestinal perfusion technique. The low solubility of UC-781 required the use of solubility/dissolution rate enhancing agents (e.g. VitE-TPGS, Gelucire 44/14). The creation of sink conditions in the receiver compartment of the Caco-2 system was a prerequisite to reliably study the transport of this poorly soluble compound. After inclusion of VitE-TPGS in the acceptor solution, UC-781 could be characterized as a class II drug of the Biopharmaceutical Classification System (low solubility, high permeation across membranes). A significant concentration-dependent decrease in transport of UC-781 was observed upon increasing the concentration of VitE-TPGS in the apical compartment. This observation contrasts to the absorption enhancing properties of VitE-TPGS, and can probably be attributed to a decrease in the concentration of free UC-781 when using higher concentrations of the solubility/dissolution rate enhancing agents. The use of Gelucire 44/14 as a solubilizing agent resulted in a batch-dependent degradation of UC-781. The inclusion of the solubility/dissolution rate-enhancing agent VitE-TPGS did not result in absorption enhancement in the intestinal perfusion technique. | lld:pubmed |
| pubmed-article:11839442 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11839442 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11839442 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11839442 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11839442 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11839442 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11839442 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11839442 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11839442 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:11839442 | pubmed:issn | 0378-5173 | lld:pubmed |
| pubmed-article:11839442 | pubmed:author | pubmed-author:KingetRR | lld:pubmed |
| pubmed-article:11839442 | pubmed:author | pubmed-author:De ClercqEE | lld:pubmed |
| pubmed-article:11839442 | pubmed:author | pubmed-author:Van GelderJJ | lld:pubmed |
| pubmed-article:11839442 | pubmed:author | pubmed-author:BalzariniJJ | lld:pubmed |
| pubmed-article:11839442 | pubmed:author | pubmed-author:AugustijnsPP | lld:pubmed |
| pubmed-article:11839442 | pubmed:author | pubmed-author:NaesensLL | lld:pubmed |
| pubmed-article:11839442 | pubmed:author | pubmed-author:IngelsFF | lld:pubmed |
| pubmed-article:11839442 | pubmed:author | pubmed-author:Van den... | lld:pubmed |
| pubmed-article:11839442 | pubmed:author | pubmed-author:De BuckSS | lld:pubmed |
| pubmed-article:11839442 | pubmed:author | pubmed-author:DefermeSS | lld:pubmed |
| pubmed-article:11839442 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11839442 | pubmed:day | 2 | lld:pubmed |
| pubmed-article:11839442 | pubmed:volume | 234 | lld:pubmed |
| pubmed-article:11839442 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11839442 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11839442 | pubmed:pagination | 113-9 | lld:pubmed |
| pubmed-article:11839442 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11839442 | pubmed:meshHeading | pubmed-meshheading:11839442... | lld:pubmed |
| pubmed-article:11839442 | pubmed:meshHeading | pubmed-meshheading:11839442... | lld:pubmed |
| pubmed-article:11839442 | pubmed:meshHeading | pubmed-meshheading:11839442... | lld:pubmed |
| pubmed-article:11839442 | pubmed:meshHeading | pubmed-meshheading:11839442... | lld:pubmed |
| pubmed-article:11839442 | pubmed:meshHeading | pubmed-meshheading:11839442... | lld:pubmed |
| pubmed-article:11839442 | pubmed:meshHeading | pubmed-meshheading:11839442... | lld:pubmed |
| pubmed-article:11839442 | pubmed:meshHeading | pubmed-meshheading:11839442... | lld:pubmed |
| pubmed-article:11839442 | pubmed:meshHeading | pubmed-meshheading:11839442... | lld:pubmed |
| pubmed-article:11839442 | pubmed:meshHeading | pubmed-meshheading:11839442... | lld:pubmed |
| pubmed-article:11839442 | pubmed:meshHeading | pubmed-meshheading:11839442... | lld:pubmed |
| pubmed-article:11839442 | pubmed:meshHeading | pubmed-meshheading:11839442... | lld:pubmed |
| pubmed-article:11839442 | pubmed:meshHeading | pubmed-meshheading:11839442... | lld:pubmed |
| pubmed-article:11839442 | pubmed:meshHeading | pubmed-meshheading:11839442... | lld:pubmed |
| pubmed-article:11839442 | pubmed:meshHeading | pubmed-meshheading:11839442... | lld:pubmed |
| pubmed-article:11839442 | pubmed:meshHeading | pubmed-meshheading:11839442... | lld:pubmed |
| pubmed-article:11839442 | pubmed:meshHeading | pubmed-meshheading:11839442... | lld:pubmed |
| pubmed-article:11839442 | pubmed:meshHeading | pubmed-meshheading:11839442... | lld:pubmed |
| pubmed-article:11839442 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:11839442 | pubmed:articleTitle | Intestinal absorption characteristics of the low solubility thiocarboxanilide UC-781. | lld:pubmed |
| pubmed-article:11839442 | pubmed:affiliation | Laboratory of Pharmacotechnology and Biopharmacy, Katholieke Universiteit Leuven, O&N, Gasthuisberg, 3000 Leuven, Belgium. | lld:pubmed |
| pubmed-article:11839442 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11839442 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11839442 | lld:pubmed |
